BNP Paribas Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

BNP Paribas Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-37,058	Closed	-$124K	–	1121
2016 Q3	$124K	Hold	37,058	–	–	﹤0.01%	1077
2016 Q2	$116K	Hold	37,058	–	–	﹤0.01%	1082
2016 Q1	$123K	Hold	37,058	–	–	﹤0.01%	1061
2015 Q4	$131K	Buy	+37,058	New	+$155K	﹤0.01%	1060

Other funds holding PDLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BNP Paribas Asset Management's PDLI Position: Q4 2016 in Review

BNP Paribas Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 37,058 shares — an estimated $124K sold.

BNP Paribas Asset Management first reported a position in PDLI in Q4 2015 and held it in 4 quarters. The position peaked at $131K in Q4 2015. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

BNP Paribas Asset Management reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
BNP Paribas Asset Management sold 37,058 PDL BioPharma, Inc. shares in Q4 2016, an estimated $124K.
BNP Paribas Asset Management first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 4 quarters.
BNP Paribas Asset Management's PDL BioPharma, Inc. position peaked at $131K in Q4 2015.
190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on BNP Paribas Asset Management's 13F filing for Q4 2016, filed 31 Jan 2017.